Lv4
584 积分 2025-02-08 加入
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
16小时前
已完结
Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers
1天前
已完结
The therapeutic window of antibody drug conjugates: A dogma in need of revision
1天前
已完结
Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer
6天前
已完结
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer
6天前
已完结
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
6天前
已完结
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer
6天前
已完结
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
6天前
已完结
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
6天前
已完结
Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer
7天前
已完结
皖公网安备34019202002308
